Analyst Ratings For Agios Pharmaceuticals (NASDAQ:AGIO)
Today, Credit Suisse Group reiterated its Outperform rating on Agios Pharmaceuticals (NASDAQ:AGIO) with a price target of $80.00.
Some recent analyst ratings include
- 2/15/2018-Credit Suisse Group Reiterated Rating of Outperform.
- 2/14/2018-Oppenheimer was Downgraded by analysts at Oppenheimer from a “Outperform ” rating to a ” Market Perform” rating.
- 12/5/2017-Cann Reiterated Rating of Buy.
Recent Insider Trading Activity For Agios Pharmaceuticals (NASDAQ:AGIO)
Agios Pharmaceuticals (NASDAQ:AGIO) has insider ownership of 5.43% and institutional ownership of 82.74%.
- On 2/5/2018 Scott Biller, Insider, sold 3,000 with an average share price of $76.04 per share and the total transaction amounting to $228,120.00.
- On 2/1/2018 Christopher Bowden, Insider, sold 2,000 with an average share price of $78.75 per share and the total transaction amounting to $157,500.00.
- On 2/1/2018 David P Schenkein, CEO, sold 13,000 with an average share price of $78.75 per share and the total transaction amounting to $1,023,750.00.
- On 1/26/2018 David P Schenkein, CEO, sold 23,572 with an average share price of $81.09 per share and the total transaction amounting to $1,911,453.48.
- On 1/24/2018 David P Schenkein, CEO, sold 46,408 with an average share price of $80.01 per share and the total transaction amounting to $3,713,104.08.
- On 1/23/2018 Corp /De/ Celgene, Major Shareholder, bought 851,154 with an average share price of $67.00 per share and the total transaction amounting to $57,027,318.00.
- On 1/23/2018 Steven L Hoerter, Insider, sold 25,000 with an average share price of $74.83 per share and the total transaction amounting to $1,870,750.00.
Recent Trading Activity for Agios Pharmaceuticals (NASDAQ:AGIO)
Shares of Agios Pharmaceuticals closed the previous trading session at 78.70 up +0.73 0.94% with 76.3563003540039 shares trading hands.